Contributions
Abstract: P619
Type: Poster
Abstract Category: Therapy - disease modifying - Immunomodulation/Immunosuppression
Fingolimod is an oral treatment for patients with relapsing-remitting multiple sclerosis (MS). There has been no data regarding effects of fingolimod on cognition and a lack of evidence about its long term cognitive results in real-world populations. The aim of the study was to investigate the effects of fingolimod treatment on cognitive function in three years period. The patients included in this multi-centre, examiner-blinded, and prospective study were the adults with RRMS who initiated fingolimod treatment. They were followed up at three centres in Turkey. Patients with Expanded Disability Status Scale (EDSS) scores of 5.5 points or less enrolled in the study. To maintain treatment blinding, we used the two-physician principle: a treating neurologist and an evaluating neurologist. Neurological evaluations and cognitive tests were performed at baseline and every six months for 3 years. Age, sex and education-matched healthy control people were also evaluated cognitively at the same scheduled visits. For cognitive evaluation the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery, which included the Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test-2 (CVLT2) and the Brief Visuospatial Memory Test-Revised (BVMT-R) used. A total of 105 patients (79 female, mean age: 35.1±8) and 98 healthy control (74 female, mean age: 33.8±8.4) included in the study. SDMT score improved at month 6 vs baseline (41.3 vs. 42.7, p= 0.034. BVMTR score also improved at month 6
(25.7 vs. 26.9, p=0.02). CVLT2 improved from 49.1 to 51, p=0.03). 37 patients (35.2%) were found to be cognitively impaired at study entry on the basis of SDMT under -1 SD. At follow-up, 24 patients were cognitively impaired (p=0.009). Number of cognitively impaired patients decreased from 39 to 28 on the basis of CVLT, and 35 to 19 on the basis of BVMTR at month 6. Patients were stable at month 36. There were significantly less number of patients who had scores under -1 SD on SDMT after 3 years. All the cognitive function variables were significantly improved in the patients who had started fingolimod treatment due to the side effects of previous treatment (p< 0.05), whereas there was no such a significant difference in the patients who had changed the previous treatment due to its ineffectiveness (p>0.05). The results of this study have indicated that fingolimod treatment was effective on cognitive functions in patients with relapsing-remitting MS.
Disclosure:
Serkan Ozakbas: nothing to disclose,
Pinar Yigit: nothing to disclose
Turhan Kahraman: nothing to disclose
Bilge Piri Cinar: nothing to disclose
Gorkem Kosehasanogullari: nothing to disclose
Zaur Mehdiyev: nothing to disclose
Abstract: P619
Type: Poster
Abstract Category: Therapy - disease modifying - Immunomodulation/Immunosuppression
Fingolimod is an oral treatment for patients with relapsing-remitting multiple sclerosis (MS). There has been no data regarding effects of fingolimod on cognition and a lack of evidence about its long term cognitive results in real-world populations. The aim of the study was to investigate the effects of fingolimod treatment on cognitive function in three years period. The patients included in this multi-centre, examiner-blinded, and prospective study were the adults with RRMS who initiated fingolimod treatment. They were followed up at three centres in Turkey. Patients with Expanded Disability Status Scale (EDSS) scores of 5.5 points or less enrolled in the study. To maintain treatment blinding, we used the two-physician principle: a treating neurologist and an evaluating neurologist. Neurological evaluations and cognitive tests were performed at baseline and every six months for 3 years. Age, sex and education-matched healthy control people were also evaluated cognitively at the same scheduled visits. For cognitive evaluation the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery, which included the Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test-2 (CVLT2) and the Brief Visuospatial Memory Test-Revised (BVMT-R) used. A total of 105 patients (79 female, mean age: 35.1±8) and 98 healthy control (74 female, mean age: 33.8±8.4) included in the study. SDMT score improved at month 6 vs baseline (41.3 vs. 42.7, p= 0.034. BVMTR score also improved at month 6
(25.7 vs. 26.9, p=0.02). CVLT2 improved from 49.1 to 51, p=0.03). 37 patients (35.2%) were found to be cognitively impaired at study entry on the basis of SDMT under -1 SD. At follow-up, 24 patients were cognitively impaired (p=0.009). Number of cognitively impaired patients decreased from 39 to 28 on the basis of CVLT, and 35 to 19 on the basis of BVMTR at month 6. Patients were stable at month 36. There were significantly less number of patients who had scores under -1 SD on SDMT after 3 years. All the cognitive function variables were significantly improved in the patients who had started fingolimod treatment due to the side effects of previous treatment (p< 0.05), whereas there was no such a significant difference in the patients who had changed the previous treatment due to its ineffectiveness (p>0.05). The results of this study have indicated that fingolimod treatment was effective on cognitive functions in patients with relapsing-remitting MS.
Disclosure:
Serkan Ozakbas: nothing to disclose,
Pinar Yigit: nothing to disclose
Turhan Kahraman: nothing to disclose
Bilge Piri Cinar: nothing to disclose
Gorkem Kosehasanogullari: nothing to disclose
Zaur Mehdiyev: nothing to disclose